Kinetics and thermodynamics of irreversible inhibition of matrix metalloproteinase 2 by a Co(III) Schiff base complex
- 327 Downloads
Cobalt(III) Schiff base complexes have been used as potent inhibitors of protein function through the coordination to histidine residues essential for activity. The kinetics and thermodynamics of the binding mechanism of Co(acacen)(NH3)2Cl [Co(acacen); where H2acacen is bis(acetylacetone)ethylenediimine] enzyme inhibition has been examined through the inactivation of matrix metalloproteinase 2 (MMP-2) protease activity. Co(acacen) is an irreversible inhibitor that exhibits time- and concentration-dependent inactivation of MMP-2. Co(acacen) inhibition of MMP-2 is temperature-dependent, with the inactivation increasing with temperature. Examination of the formation of the transition state for the MMP-2/Co(acacen) complex was determined to have a positive entropy component indicative of greater disorder in the MMP-2/Co(acacen) complex than in the reactants. With further insight into the mechanism of Co(acacen) complexes, Co(III) Schiff base complex protein inactivators can be designed to include features regulating activity and protein specificity. This approach is widely applicable to protein targets that have been identified to have clinical significance, including matrix metalloproteinases. The mechanistic information elucidated here further emphasizes the versatility and utility of Co(III) Schiff base complexes as customizable protein inhibitors.
KeywordsProtein inhibition Histidine Matrix metalloproteinase Cobalt
The authors gratefully acknowledge M. Heffern for helpful discussion. Fluorescence measurements were performed at the Northwestern University High Throughput Analysis Laboratory. Metal analysis was performed at the Northwestern University Quantitative Bioelemental Imaging Center, generously supported by NASA Ames Research Center (NNA04CC36G). This work was supported by the National Institutes of Health’s Centers of Cancer Nanotechnology Excellence initiative of the National Cancer Institute under award U54CA119341.
- 15.Jezierska A, Motyl T (2009) Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 15(2):RA32–40Google Scholar
- 20.Segel IH (1975) Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. Wiley, New YorkGoogle Scholar
- 22.Laidler KJ, Meiser JH (1982) Physical chemistry. Benjamin/Cummings, Menlo ParkGoogle Scholar
- 23.Bode W, Gomis-Rueth F-X, Stoeckler W (1993) Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the ‘metzincins’. FEBS Lett 331(1–2):134–140PubMedCrossRefGoogle Scholar
- 25.Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM (2010) To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta Mol Cell Res 1803(1):72–94Google Scholar
- 29.Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man C-F, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C et al (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 282(38):27781–27791PubMedCrossRefGoogle Scholar